ArticleIn silico pharmacology2025
Comprehensive immunoinformatics guided design and in silico assessment of a multi-epitope vaccine to elicit immunity against Mayaro virus.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Mayaro virus (MAYV), an emerging arbovirus of the Alphavirus genus (family Togaviridae), shares clinical and epidemiological features with other arboviruses such as Chikungunya, Dengue, and Zika. It causes Mayaro fever in humans, characterized by febrile illness and prolonged arthralgia, often leading to misdiagnosis. Given the absence of licensed vaccines or antiviral therapies and the presence of competent vectors in endemic regions, MAYV poses a significant threat of epidemic, particularly in rural South America. In this research, computational immunological methods were employed to construct a polypeptide vaccine, with a focus on the structural polyprotein of the Mayaro virus. A series of rigorous computational assessments were used to predict the most potent T and B lymphocyte epitopes for the vaccine candidate. The vaccine exhibited favorable physicochemical properties, stable secondary and tertiary structures, and high solubility. Molecular dynamics simulations demonstrated its structural stability, while docking studies indicated robust interactions with TLR2 and TLR4 receptors, essential for initiating immune responses. Codon optimization, along with in silico cloning, demonstrated efficient expression of the vaccine candidate in an Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00387-5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.